Announced details
Drug discovery, biotech industry, pharmaceuticals, medical devices, regenerative medicine products and medical technologies
45 member companies (as of the end of March 2026)
Our representative director and president, Adachi Kiichi (安達 喜一), has assumed the chairmanship of the council. Other capital, personnel and business relationships: not disclosed.
Established in July 2009 as a voluntary association by 20 biotech-related companies, the organization became a general incorporated association in April 2019. As of the end of March 2026, it had 45 member companies, comprising 40 regular members and 5 supporting members. Its members are companies working on innovation in healthcare fields, including pharmaceuticals, medical devices, regenerative medicine products and medical technologies.
45 member companies (as of the end of March 2026: 40 regular members and 5 supporting members)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Japan Biotech Council website (http://samurai-biotech.jp/)
| Item | Details |
|---|---|
| Counterparty | Japan Biotech Council |
| Counterparty overview | Established in July 2009 as a voluntary association by 20 biotech-related companies, the organization became a general incorporated association in April 2019. As of the end of March 2026, it had 45 member companies, comprising 40 regular members and 5 supporting members. Its members are companies working on innovation in healthcare fields, including pharmaceuticals, medical devices, regenerative medicine products and medical technologies. |
| Relationship with the Company | Our representative director and president, Adachi Kiichi (安達 喜一), has assumed the chairmanship of the council. Other capital, personnel and business relationships: not disclosed. |
| Launch date | 21 May 2026 (already assumed office) |
| Applicable area | Drug discovery, biotech industry, pharmaceuticals, medical devices, regenerative medicine products and medical technologies |
| Location scale | 45 member companies (as of the end of March 2026: 40 regular members and 5 supporting members) |
| Usage history | 45 member companies (as of the end of March 2026) |
| Source | Japan Biotech Council website (http://samurai-biotech.jp/) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The council will promote collaboration with member companies and relevant institutions, public-private dialogue, policy recommendations, institutional development and international cooperation to strengthen Japan’s drug discovery capabilities and the competitiveness of its biotech industry.